Generated by AI
Can-Fite BioPharma Ltd. ADR is a clinical-stage biopharmaceutical company focused on developing orally administered small-molecule therapies for cancer, liver diseases, inflammatory conditions, and erectile dysfunction. The company’s current pipeline centers on drug candidates designed to modulate the A3 adenosine receptor, a biological target associated with inflammatory and cancer-related pathways. Its product portfolio includes programs such as Piclidenoson, Namodenoson, and CF602, reflecting a research model built around targeted treatments for serious unmet medical needs. Can-Fite BioPharma also works on cannabinoid-based programs and biomarker tools that support patient selection and therapeutic development. Headquartered in Israel, the company operates as a specialist drug developer within the global biotechnology sector, where it plays a role in advancing precision-oriented therapies from clinical research toward potential medical use.
Website26 Ben Gurion Street
Ramat Gan, 5257346
Israel
The latest articles about CANF.
The study evaluates oral Piclidenoson and last patient in the interim-analysis cohort completes treatment Ramat Gan, Israel, Nov. 18, 2026 (GLO...
Patient from the Company’s completed Phase II study remains cancer-free and in good health at the ten-year survival milestone Ramat Gan, Israel, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a clinical-stage biotechnology company developing a pipeline of proprietary small molecule drugs targeting oncological and inflammatory diseases, today announced that a patient with advanced liver cancer who participated in its completed Phase II study of Namod
Summary of Sep 2's posts. Generated by AI.
Summary of Sep 2's posts. Generated by AI.
Summary of Sep 2's posts. Generated by AI.
Investors talking about CANF also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.